Technology | June 15, 2009

Philips Debuts Scalable SPECT, Workstation, Third-Gen Time-of-Flight PET

June 16, 2009 - Royal Philips Electronics showed at the 2009 SNM Annual Conference its new BrightView X, a scalable SPECT camera that can be easily upgraded with CT when physicians are ready for the full capabilities of BrightView XCT, a nuclear medicine workstation and the third-generation time-of-flight PET.

Launching at SNM, Philips new BrightView X is a scalable version of the BrightView XCT. The mid-level SPECT camera offers a cost-effective option that allows customers the flexibility to purchase SPECT now and add CT later. The transition involves a simple upgrade without a change to the room size or power requirements.

SPECT/CT has long been utilized in cardiac studies, but with Philips' upgraded BrightView XCT there is promise for applications in orthopedic studies, which is a field that typically relies heavily on X-ray imaging. At SNM 2009, Philips is showing the first SPECT/CT hybrid system to address physicians’ needs for high-quality localization and attenuation correction with a flat-panel CT, while still allowing for patient dose reduction and increased diagnostic confidence, the company said.

To improve image registration, Philips BrightView XCT uses a co-planar design that allows the acquisition of SPECT and CT with minimal table movement between scans in most cases. Reducing movement, along with the system’s wide-open gantry and large bore, contribute to improved patient comfort. Flexible breathing protocols also set it apart from other systems by allowing patients to breath normally during both SPECT and CT scans.

Along with the addition of the new Nuclear Medicine Application Suite on the Extended Brilliance Workstation, nuclear medicine is now available with the BrightView XCT; SPECT, PET and CT processing can all be accessed on one common platform, helping to speed diagnosis and streamline workflow. The BrightView XCT is a general purpose nuclear medicine SPECT/CT camera that was introduced at last year’s SNM, but is being shown with expanded applications in orthopedics at this year's SNM conference.

Philips is also introducing the third-generation Time-of-Flight platform for oncology on its GEMINI TF PET/CT. Time-of-flight technology measures the actual time difference between the detection of coincident gamma rays for more accurate localization, producing a higher quality image and allowing for lower tracer dose amounts in patients and shorter imaging times. According to Philips, the system is the first commercial PET/CT scanner to break the 500 Pico-second barrier, with the speed to measure a photon within seven centimeters accuracy traveling seven times around the earth in a single second.

Philips newest Time-of-Flight system, which was launched at SNM 2008, the GEMINI TF Big Bore PET/CT, is specifically designed for radiation oncologists and their patients. The Big Bore offers excellent lesion detection for diagnosis and staging with Philips revolutionary TruFlight Time-of-Flight PET technology. The system has been installed at three sites throughout the U.S., including the first installation at a proton therapy center at the University of Pennsylvania.

For more information: www.philips.com/newscenter

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Carestream dose management
Sponsored Content | Whitepapers | Advanced Visualization | August 17, 2017
It's critical for today's healthcare professionals to understand the balance between the risks and benefits of any X-...
Carestream Launches MR Brain Perfusion and Diffusion Modules for Vue PACS
Technology | Advanced Visualization | August 16, 2017
Carestream Health recently introduced new MR (magnetic resonance) Brain Perfusion and MR Brain Diffusion modules that...
CDN to Integrate Advanced Cardiac Imaging Tools From DiA Imaging Analysis
Technology | Advanced Visualization | August 10, 2017
August 10, 2017 — CDN recently announced a new partnership agreement with DiA Imaging Analysis Ltd., makers of next-g
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
GE Additive and Stryker Announce Additive Manufacturing Partnership
News | 3-D Printing | July 06, 2017
July 6, 2017 — GE Additive and Stryker have entered a partnership agreement to support Stryker’s growth in...
Philips Receives FDA 510(k) Clearance for IntelliSpace Portal 9.0
Technology | Advanced Visualization | June 29, 2017
Philips announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Overlay Init